Is Wegovy worth the risk? What the side-effect evidence actually shows

What side effects do most people actually experience on Wegovy?

The short answer: digestive ones. Nausea is the most commonly reported effect across the STEP trial programme, it tends to peak in the days after starting or increasing the dose, then settles for most people within two to three weeks. Constipation, loose stools, indigestion and burping also appear in the data with reasonable frequency. Fatigue and mild headaches are reported too, particularly early in treatment.

None of that should be minimised. For some people the nausea is significant enough that they need to slow the dose titration, and that is exactly what the escalation schedule exists for. A prescriber controls that pace; it is not something to self-adjust. The full side-effect profile for Wegovy covers the frequency data in more detail, but the practical takeaway is that most people experience some GI disruption and most find it manageable once their system adjusts.

Less commonly, injection-site reactions, dizziness and reflux are reported. These are real, not trivial, but they affect a smaller proportion of patients and rarely require stopping treatment altogether.

Which risks are serious enough to warrant urgent medical attention?

This is where balance tips into directness. Acute pancreatitis (inflammation of the pancreas) is an infrequent but serious risk with GLP-1 medicines including semaglutide. In January 2026, the MHRA's Drug Safety Update formally highlighted this: severe stomach pain that radiates toward the back, with or without vomiting, should prompt urgent medical help rather than a wait-and-see approach.

Gallbladder problems, including gallstones, have also been observed in trial populations. Symptoms are easy to confuse with ordinary indigestion (pain in the upper right abdomen, especially after eating) so the rule is simple: if it's persistent or severe, get it checked. Dehydration from prolonged vomiting or diarrhoea can strain the kidneys, which is worth knowing before any bank-holiday weekend away.

For anyone taking Wegovy who notices signs of an allergic reaction (swelling around the face, throat or tongue, difficulty breathing), that is an emergency. More detail on the range of serious side effects associated with Wegovy is available for those who want a deeper look before starting.

Who should be particularly cautious, and what does 'worth the risk' depend on?

Whether Wegovy is appropriate depends on the individual. There are clear contraindications: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, history of pancreatitis, and certain gastrointestinal conditions require a prescriber to say no or proceed very carefully. Wegovy is not licensed for people under 18, and it is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, the NHS England guidance on weight management injections sets this out clearly.

For people without those contraindications and with a BMI that meets the licensed threshold, the evidence from the STEP 1 trial showed around 15% average weight loss over 68 weeks, a meaningful reduction that carries its own health benefits, particularly for blood pressure, blood sugar and cardiovascular risk. That context matters when weighing side effects against outcomes. A fuller look at Wegovy's risk profile across different health conditions can help frame that comparison.

One thing our clinical team hears regularly: people worry about risks they've read about online but haven't had the chance to contextualise. The consultation exists precisely for that, it is the place to raise your history, your concerns, and your questions before a prescription is ever considered. If Wegovy isn't the right fit, semaglutide isn't the only licensed option; a comparison of available weight-loss treatments may help clarify which direction makes sense.

How does Wegovy's risk profile compare with doing nothing?

It is a question worth asking seriously. Obesity is itself a significant health risk, it is associated with type 2 diabetes, cardiovascular disease, obstructive sleep apnoea and several cancers. That does not mean every side effect of treatment is acceptable, but it does mean that the risk-benefit calculation is rarely one-sided. A treatment with a nausea rate of 40-50% in its first weeks looks different when set against a condition with long-term consequences that are far harder to reverse.

The comparison between Wegovy and Saxenda (liraglutide) in terms of side effects is a useful reference point if you are weighing options, the GI profiles are broadly similar, though the mechanisms differ. For a broader look at how Wegovy fits into the treatment landscape, the Wegovy overview page covers the full picture. And if the cost of treatment is part of your thinking, the Wegovy pricing guide explains what a legitimate private prescription includes.

If you want to discuss your specific history before making any decision, our prescribers cover suitability and side effects as part of the free consultation, there is no obligation to proceed. Start your free consultation and get a clinical view that is actually about you.